therapy

Lilly Shares Drop As Cancer Therapy Lartruvo Fails Study

Lilly Shares Drop As Cancer Therapy Lartruvo Fails Study

Eli Lilly & Co. (NYSE: LLY) said on Friday its cancer treatment Lartruvo, approved on an accelerated basis in 2016, failed to improve patient survival in a long-term study and will no longer be prescribed, driving shares down 3%.The Company said..

Juno Shares Surge on Celgene’s $9 Billion Acquisition

Juno Shares Surge on Celgene’s $9 Billion Acquisition

Juno Therapeutics Inc. (NASDAQ: JUNO) shares continued to surge on Monday after Celgene Corp. (NASDAQ: CELG) had entered into an agreement to acquire Juno for a total of $9 billion or $87 per share. Juno shares rose 27 percent during Monday&rsq..

Spark Therapeutics offers to cure blindness for $850,000

Spark Therapeutics offers to cure blindness for $850,000

Spark Therapeutics Inc (NASDAQ: ONCE) Luxturna, the first gene therapy in the U.S., has been approved by the Food and Drug Administration. The gene therapy is intended to treat a rare, inherited retinal disease that could possibly cause blindness. U..

National Institute of Health partners with 11 Biopharma companies for Cancer Research

National Institute of Health partners with 11 Biopharma companies for Cancer Research

The National Institutes of Health and 11 biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT). This is a five-year-public-private research collaboration totaling $215 million as part of the Cancer Moons..